Idiopathic Membranous Nephropathy Therapeutics Market Size (7MM) was found to be ~USD 130 Million in 2025 and It is projected to grow at a CAGR of 8.2% by 2036, estimates DelveInsight

Idiopathic Membranous Nephropathy Therapeutics Market Size (7MM) was found to be ~USD 130 Million in 2025 and It is projected to grow at a CAGR of 8.2% by 2036, estimates DelveInsight

DelveInsight's "Idiopathic Membranous Nephropathy Market Insights, Epidemiology, and Market Forecast-2036" report delivers an in-depth understanding of Idiopathic Membranous Nephropathy, historical and forecasted epidemiology, as well as the Idiopathic Membranous Nephropathy market trends in the United States, EU4 (Germany, Spain, Italy, and France), the United Kingdom, and Japan.

Key Takeaways from the Idiopathic Membranous Nephropathy Market Report
• In January 2026, the European Medicines Agency (EMA) granted Priority Medicines (PRIME) designation to povetacicept for primary membranous nephropathy, expediting its evaluation process.
• In November 2025, the FDA granted Fast Track Designation to povetacicept for primary membranous nephropathy, recognizing the significant unmet need in this patient population.
• According to DelveInsight's estimates, in 2025, the total number of prevalent cases of Idiopathic Membranous Nephropathy in the 7MM was approximately 89,000 cases.
• In 2025, the United States held the largest market share for Idiopathic Membranous Nephropathy among the 7MM, accounting for approximately 60% of the total market (~USD 85 million).
• PLA2R antigen was detected in approximately 23,000 of Idiopathic Membranous Nephropathy patients in the US, with THSD7A present in approximately 800 cases, representing distinct disease subtypes with varying prognosis.
• Among EU4 and the UK, Germany had the highest prevalent population of Idiopathic Membranous Nephropathy with approximately 6,000 cases, followed by the UK with 5,000 cases in 2025.
• Rituximab has emerged as the preferred first-line immunosuppressive therapy, achieving durable remission rates of 35-45%, and is expected to maintain significant market presence despite emerging alternatives.
• The leading Idiopathic Membranous Nephropathy companies such as Cerium Pharmaceuticals, Hoffmann-La-Roche, Biogen, BeOne Medicines Ltd., and others.
• Promising Idiopathic Membranous Nephropathy Therapies such as SNP-ACTH (1-39), povetacicept, GAZYVA (Obinutuzumab), MOR202 (felzartamab), BRUKINSA (Zanubrutinib), and others.

Stay ahead in the Idiopathic Membranous Nephropathy Therapeutics Market with DelveInsight's Strategic Report @ https://www.delveinsight.com/infographics/idiopathic-membranous-nephropathy-imn-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Idiopathic Membranous Nephropathy Epidemiology Segmentation in the 7MM
• Patient Burden Assessment
• Total Diagnosed Prevalent Cases of Idiopathic Membranous Nephropathy
• Antigen-Specific Cases (PLA2R, THSD7A, NELL-1, Sema3B)
• Treated Cases of Idiopathic Membranous Nephropathy
• Disease Severity-based Classification (Low-risk, Moderate-risk, High-risk)
• Age-specific and Gender-specific Incident Cases
• Stage-specific Incident Cases of Idiopathic Membranous Nephropathy (Early, Progressive, End-Stage Renal Disease)
• Comorbidity-Associated Cases (Infections, Autoimmune Disorders, Malignancy-Associated)
• Response-Based Patient Segmentation (Responders, Partial Responders, Refractory Cases)

Download the report to understand which factors are driving Idiopathic Membranous Nephropathy epidemiology trends @ https://www.delveinsight.com/infographics/idiopathic-membranous-nephropathy-imn-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Idiopathic Membranous Nephropathy Pipeline AnalysisSNP-ACTH (1-39) Gel: Cerium Pharmaceuticals

SNP-ACTH (1-39) Gel is a subcutaneous formulation of synthetic porcine ACTH peptide in development as a first-line immunosuppressive therapy for primary membranous nephropathy. A Phase III randomized superiority trial is currently underway comparing SNP-ACTH (1-39) Gel versus rituximab in moderate- to high-risk PMN patients. Preclinical studies and Phase I data have demonstrated safety, tolerability, and potency. The company received FDA Orphan Drug Designation in June 2023 and has secured USD 19 million in total funding to advance this asset, with an estimated annual US cost of USD 105,936 and anticipated launch in 2027.

Povetacicept (ALPN-303): Alphamab Oncology
Povetacicept is a novel B7-2 costimulation molecule inhibitor designed to modulate T-cell activation and reduce pathogenic autoimmune responses in primary membranous nephropathy. In November 2025, the FDA granted Fast Track Designation, and in January 2026, the EMA awarded PRIME designation for accelerated evaluation. Updated data from the ongoing RUBY-3 trial presented at American Society of Nephrology (ASN) Kidney Week 2025 demonstrated significant proteinuria reduction and renal function preservation. Estimated annual US cost is approximately USD 85,000, with anticipated launch expected by 2028-2029.

GAZYVA (Obinutuzumab): Hoffmann-La-Roche
Obinutuzumab is an anti-CD19 monoclonal antibody currently in Phase III development for primary membranous nephropathy (pMN). Real-world retrospective studies have demonstrated strong efficacy, achieving immunological remission rates of 92.0% and clinical remission rates of 83.6%, with significant improvements in proteinuria, serum albumin, and kidney function over median 13-month follow-up. The drug shows efficacy in both rituximab-naïve and rituximab-refractory populations, as well as in anti-PLA2R-negative patients, positioning it as a promising alternative first-line therapy.

MOR202 (Felzartamab): Biogen
MOR202 is a monoclonal antibody targeting CD38 currently in Phase III trials for adult participants with primary membranous nephropathy. Its mechanism provides dual benefits through direct podocyte protection and immune modulation. Preliminary data suggests potential for inducing sustained remission in steroid-resistant and difficult-to-treat PMN populations. Expected regulatory decision targeted for 2029-2030.

BRUKINSA (Zanubrutinib): BeiGene
BRUKINSA is a Bruton's tyrosine kinase (BTK) inhibitor being evaluated for idiopathic membranous nephropathy management. BTK inhibition reduces pathogenic anti-PLA2R autoantibody production, limits immune complex formation, and dampens inflammatory signaling. Ongoing clinical studies are evaluating its efficacy as both monotherapy and combination therapy with conventional immunosuppression. This represents a paradigm shift toward targeted B-cell directed therapy in IMN treatment.

Idiopathic Membranous Nephropathy Drugs Market Insights
The idiopathic membranous nephropathy market is undergoing significant transformation, driven by advances in biomarker identification and targeted therapeutic development. Circulating autoantibody monitoring, particularly anti-PLA2R and anti-THSD7A assays, has enhanced disease diagnosis, risk stratification, and treatment response monitoring, with declining antibody levels preceding clinical remission in up to 80% of cases.

Emerging therapies are shifting the treatment paradigm toward more targeted immunomodulation. Melanocortin receptor agonists like SNP-ACTH exert direct podocyte-protective effects and demonstrate remission rates of 40-50% in clinical trials. Costimulation modulators such as povetacicept offer novel mechanisms for T-cell regulation, achieving proteinuria remission in 45-60% of treated patients.

Real-world utilization data reveals that immunosuppressive therapy adoption remains suboptimal, with only 35-40% of eligible patients receiving advanced therapies despite available treatment options. Treatment resistance occurs in approximately 30-35% of patients on conventional immunosuppression, driving the need for alternative therapeutic strategies.

Get In-Depth Knowledge on Idiopathic Membranous Nephropathy Market Trends and Forecasts with DelveInsight @ https://www.delveinsight.com/infographics/idiopathic-membranous-nephropathy-imn-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Idiopathic Membranous Nephropathy Market Outlook
Idiopathic Membranous Nephropathy (IMN) is a rare but significant glomerular disorder representing the leading cause of nephrotic syndrome in Caucasian adults (~30% of cases), predominantly affecting men aged 30-50 years. The disease is characterized by immune-mediated podocyte injury, resulting in proteinuria, hypoalbuminemia, and nephrotic syndrome.
Current management relies primarily on supportive care with renin-angiotensin system blockade and blood pressure control, followed by immunosuppressive therapies in high-risk patients. Rituximab has emerged as the preferred first-line therapy, achieving 35-45% durable remission rates and sustained immunological remission in rituximab-naïve populations.
The IMN market is experiencing a critical paradigm shift driven by several converging factors. Improved biomarker-based diagnosis has enhanced disease recognition and stratification, enabling earlier intervention and risk-adapted therapy selection.
The projected market growth from USD 130 million in 2025 to USD 1,000 million by 2036 reflects multiple growth drivers: first-in-class therapy approvals, expanded treatment availability for refractory populations, improved disease awareness among clinicians and patients, and increasing diagnostic testing adoption.

Scope of the Idiopathic Membranous Nephropathy Market Report
• Coverage: 7MM
• Study Period: 2022-2036
• Forecast Period: 2026-2036
• Idiopathic Membranous Nephropathy Companies: Cerium Pharmaceuticals, Hoffmann-La-Roche, Biogen, BeOne Medicines Ltd., Alphamab Oncology, BeiGene, Vertex Pharmaceuticals, and others.
• Idiopathic Membranous Nephropathy Therapies: SNP-ACTH (1-39), Povetacicept, GAZYVA (Obinutuzumab), MOR202 (Felzartamab), BRUKINSA (Zanubrutinib), and others.

Unlock Strategic Insights with DelveInsight's Comprehensive Idiopathic Membranous Nephropathy MarketReport :https://www.delveinsight.com/infographics/idiopathic-membranous-nephropathy-imn-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=mpr

Table of Contents
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Key Events
5. Epidemiology and Market Forecast Methodology
6. Idiopathic Membranous Nephropathy (IMN) Market Overview at a Glance
7. Disease Background and Overview
8. Treatment and Management
9. Epidemiology and Patient Population
10. Patient Journey
11. Emerging Drugs
12. Idiopathic Membranous Nephropathy: Seven Major Market Analysis
13. Unmet Needs
14. SWOT Analysis
15. KOL Views
16. Market Access and Reimbursement
17. Appendix
18. DelveInsight Capabilities
19. Disclaimer
20. About DelveInsight

Media Contact
Company Name: DelveInsight
Contact Person: Mehul Malhotra
Email: mmalhotra@delveinsight.com
Phone: +919650213330
Address: 304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, the company offers customized research solutions and insights to clients across the globe.

This release was published on openPR.